Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
Background: Glucose-dependent insulinotropic peptide (GIP) is one of two incretin hormones that communicate nutrient intake with systemic metabolism. Although GIP was the first incretin hormone to be discovered, the understanding of GIP's biology was quickly outpaced by research focusing on the...
Main Author: | Jonathan E. Campbell |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-04-01
|
Series: | Molecular Metabolism |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2212877820302131 |
Similar Items
-
Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation
by: Iona Davies, et al.
Published: (2025-02-01) -
Genetic disruption of the Gipr in Apoe−/− mice promotes atherosclerosis
by: Gemma Pujadas, et al.
Published: (2022-11-01) -
Glucose-Dependent Insulinotropic Polypeptide Plasma Level Influences the Effect of n-3 PUFA Supplementation
by: Joanna Goralska, et al.
Published: (2022-08-01) -
Variation in responses to incretin therapy: Modifiable and non-modifiable factors
by: Gregory O. Austin, et al.
Published: (2023-04-01) -
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
by: Enrique Z. Fisman, et al.
Published: (2021-11-01)